Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of ...

Global Genes and Boston Children's Hospital Partner for 2025 RARE Drug Development Symposium - Equipping Rare Disease Advocates in Research and Drug Development ...

JUNE 10, 2025 — UTSA researchers in the Max and Minnie Tomerlin Voelcker CIDD Preclinical Pharmacology Core for Accelerated Drug Discovery were recently awarded a competitive grant that will allow ...

BostonGene, a leader in AI-powered solutions for drug discovery and development, is transforming how pharmaceutical companies develop, target, and deliver cancer therapies — making precision ...

Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development.

Laboratory operator Labcorp beat analysts' estimate for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.

The agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials.

There isn’t typically much money to be made developing a new drug for a small number of patients, said Christine Colvis, who heads drug development partnership programs at NCATS.

379. LabCorp LabCorp is headquartered across the Triad in Burlington. The clinical laboratory company “engages in the provision of clinical laboratory and end-to-end drug development services.

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s potential.

But can AI truly revolutionise drug development and improve success rates? AI in drug development Researchers have applied AI and machine learning to every stage of the drug development process.

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...